Specifically, SMAD6 targets pathways outside the main TGF‐β signaling route by blocking a series of interactions (TRAF6‐TAK1‐p38 MAPK/JNK) that would otherwise lead to cancer progression, aided by the A20 enzyme that removes ubiquitin labels from proteins [42]. Here, TGFB1 is linked to cancer.